Table 1.
Diseases | IVs in the MR study | Factors | p.value | 95%LCI | OR/Beta | 95%UCI |
---|---|---|---|---|---|---|
DN | 3 | 25(OH)D | 0.987 | 0.269 | 1.011 | 3.793 |
T1DN(early) | 3 | 25(OH)D | 0.726 | 0.030 | 0.587 | 11.458 |
T1DN(later) | 3 | 25(OH)D | 0.752 | 0.114 | 1.517 | 20.208 |
T2DN(early) | 3 | 25(OH)D | 0.109 | 0.001 | 0.039 | 2.075 |
T2DN(later) | 3 | 25(OH)D | 0.435 | 0.389 | 1.870 | 8.990 |
Prostate cancer | 3 | 25(OH)D | 0.087 | 0.999 | 1.008 | 1.017 |
Breast cancer | 3 | 25(OH)D | 0.092 | 0.996 | 1.027 | 1.060 |
Multiple sclerosis | 2 | 25(OH)D | 0.005 | 0.151 | 0.327 | 0.709 |
CKD(eGFRcyea) | 3 | 25(OH)D | 0.005 | -0.090 | -0.053 | -0.016 |
DM(eGFRcyea) | 3 | 25(OH)D | 0.971 | -0.355 | 0.007 | 0.369 |
DM(UACR) | 3 | 25(OH)D | 0.751 | -0.961 | 0.186 | 1.333 |
DN | 9 | BMI | 0.034 | 1.007 | 1.102 | 1.206 |
T1DN(early) | 9 | BMI | 0.700 | 0.880 | 0.979 | 1.090 |
T1DN(later) | 9 | BMI | 0.001 | 1.117 | 1.322 | 1.564 |
T2DN(early) | 8 | BMI | 0.661 | 0.832 | 1.054 | 1.336 |
T2DN(later) | 8 | BMI | 0.142 | 0.946 | 1.180 | 1.473 |
CKD(eGFRcyea) | 8 | BMI | 0.131 | -0.010 | -0.004 | 0.001 |
DM(eGFRcyea) | 8 | BMI | 0.730 | -0.017 | 0.004 | 0.024 |
DM(UACR) | 8 | BMI | 0.011 | 0.034 | 0.149 | 0.264 |
CKD(eGFRcyea) | 1 | KIM-1 | 0.016 | -0.009 | -0.005 | -0.001 |
DM(eGFRcyea) | 1 | KIM-1 | 0.043 | -0.032 | -0.016 | -0.001 |
DM(UACR) | 1 | KIM-1 | 0.652 | -0.150 | -0.028 | 0.094 |
DN | 1 | KIM-1 | 0.125 | 0.815 | 0.914 | 1.025 |
D1N(early) | 1 | KIM-1 | 0.374 | 0.753 | 0.915 | 1.113 |
D1N(later) | 1 | KIM-1 | 0.123 | 0.950 | 1.209 | 1.539 |
D2N(early) | 1 | KIM-1 | 0.227 | 0.911 | 1.160 | 1.477 |
D2N(later) | 1 | KIM-1 | 0.352 | 0.847 | 1.162 | 1.593 |
95%LCI The lower limit of 95% CI, 95%UCI The upper limit of 95% CI, T1DN Type 1 diabetic neuropathy, T2DN Type 2 diabetic neuropathy, DM Diabetic mellitus, DN Diabetic nephropathy, CKD Chronic kidney disease